• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Facing pressure in diabetes, Novo Nordisk plans next big push – obesity

November 22, 2017 By Sarah Faulkner

Novo NordiskThe world’s largest diabetes drug-maker, Novo Nordisk (NYSE:NVO), is reportedly looking to boost its efforts to treat obesity as the company’s well-established diabetes drugs face competition.

At Novo Nordisk’s capital markets day yesterday, CEO Lars Fruergaard Jorgensen told investors that the company wants to rival surgery with their drugs as a solution for obesity.

The drug-maker’s first target – semaglutide.

The weekly GLP-1 injection mimics an intestinal hormone, triggering the production of insulin. An FDA advisory committee recently voted to recommend the product for approval and Novo Nordisk expects the drug to launch as a diabetes treatment early next year, according to Reuters.

The company said it plans to launch a 4,500-patient Phase III trial in the first half of 2018 to study semaglutide as an obesity treatment.

“We are making a bet on obesity, and we believe we can ride it based on lifting efficacy. And that will create the market,” the chief executive told investors yesterday, Reuters reported.

Novo Nordisk has six obesity projects in Phase I trials and two of those candidates are slated to move to Phase II in 2018, the company said.

Its first obesity drug, Saxenda, was launched in 2015, competing with products like Roche’s Xenical and Orexigen’s Contrave.

Novo Nordisk plans to combine semaglutide with new biologics to combat obesity with results that can compete with surgery. The company said it is slated to spend more than 33% of its overall research budget on obesity drugs this year.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Novo Nordisk

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS